2305-69-3 Usage
Uses
Used in Pharmaceutical Industry:
3-Quinolinecarbonitrile, 4-hydroxy-7-methoxyis used as a key intermediate in the synthesis of various biologically active compounds and drugs. Its unique structural features make it a valuable building block for the development of new pharmaceuticals with potential therapeutic applications.
Used in Research and Development:
In the research industry, 3-Quinolinecarbonitrile, 4-hydroxy-7-methoxyis utilized for the exploration of its potential anti-inflammatory and antioxidant properties. Its structural features allow researchers to investigate its effects on various biological pathways and mechanisms, contributing to the advancement of scientific knowledge in these areas.
Used in Cancer Treatment:
3-Quinolinecarbonitrile, 4-hydroxy-7-methoxyhas been studied for its potential applications in the treatment of cancer. Its unique structural features may contribute to its ability to target and inhibit the growth of cancer cells, making it a promising candidate for further research and development in oncology.
Used in Drug Delivery Systems:
To enhance the therapeutic potential of 3-Quinolinecarbonitrile, 4-hydroxy-7-methoxy-, various drug delivery systems have been developed. These systems aim to improve the compound's bioavailability, delivery, and overall efficacy in treating diseases, including cancer. The use of organic and metallic nanoparticles as carriers for 3-Quinolinecarbonitrile, 4-hydroxy-7-methoxy-, can help overcome limitations and improve its therapeutic outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 2305-69-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,3,0 and 5 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2305-69:
(6*2)+(5*3)+(4*0)+(3*5)+(2*6)+(1*9)=63
63 % 10 = 3
So 2305-69-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H8N2O2/c1-15-8-2-3-9-10(4-8)13-6-7(5-12)11(9)14/h2-4,6H,1H3,(H,13,14)
2305-69-3Relevant articles and documents
Identification of Broad-Spectrum Dengue/Zika Virus Replication Inhibitors by Functionalization of Quinoline and 2,6-Diaminopurine Scaffolds
Kaptein, Suzanne J. F.,Vincetti, Paolo,Crespan, Emmanuele,Rivera, Jorge I. Armijos,Costantino, Gabriele,Maga, Giovanni,Neyts, Johan,Radi, Marco
supporting information, p. 1371 - 1376 (2018/07/29)
Social and demographic changes across the world over the past 50 years have resulted in significant outbreaks of arboviruses such as dengue virus (DENV) and Zika virus (ZIKV). Despite the increased threat of infection, no approved drugs or fully protectiv
Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases
Vincetti, Paolo,Caporuscio, Fabiana,Kaptein, Suzanne,Gioiello, Antimo,Mancino, Valentina,Suzuki, Youichi,Yamamoto, Naoki,Crespan, Emmanuele,Lossani, Andrea,Maga, Giovanni,Rastelli, Giulio,Castagnolo, Daniele,Neyts, Johan,Leyssen, Pieter,Costantino, Gabriele,Radi, Marco
, p. 4964 - 4975 (2015/07/02)
This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein-protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors
